Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G. Feagan, Wulf O. Böcher, Édouard Louis et al.|The Lancet|2017Cited by 449
EUS-guided fine needle aspiration and trucut needle biopsy for examination of rectal and perirectal lesionsSun‐Jin Boo, Jin-Ho Kim, Jeong‐Sik Byeon et al.|Scandinavian Journal of Gastroenterology|2011Cited by 23
812a Efficacy and Safety of Induction Therapy With the Selective IL-23 Inhibitor BI 655066, in Patients With Moderate-to-Severe Crohn's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II StudyBrian G. Feagan, Wulf O. Böcher, William J. Sandborn et al.|Gastroenterology|2016Cited by 14